Company Description
First Person Ltd., a company incorporated in Alberta, Canada, is a holding company conducting its business and operations through its wholly-owned operating subsidiaries: First Person, Inc., a Delaware corporation, and TruMed Limited, a Jamaican company limited by shares.
We intend to compete in the following three markets: 1. Functional Mushrooms.
Functional mushrooms are mushrooms believed to have additional health benefits beyond their basic nutritional value.
We intend to produce and distribute for sale full spectrum, 100 percent grain-free, organic functional mushrooms at scale.
2. Nutraceutical Products.
Nutraceuticals are products derived from food sources believed to have additional health benefits beyond their basic nutritional value.
We launched our direct-to-consumer line of highly curated cognitive supplements in March 2022. 3.
Psychedelic Mushrooms. Psychedelic mushrooms are mushrooms that contain psilocybin.
We are building a robust culture library of psychedelic mushrooms and we intend to grow and distribute psychedelic mushrooms in Jamaica.
Psilocybin is not an illegal drug under Jamaica’s Dangerous Drugs Act. We also intend to enter the psychedelic mushroom supply chain for the psychedelics market in the United States if we are able to obtain a U.S. Drug Enforcement Administration manufacturing and research registration.
| Country | Canada |
| Founded | 2021 |
| Industry | Consumer Staples |
| Sector | Personal Products |
| Employees | 9 |
| CEO | Cory J. Rosenberg |
Contact Details
Address: 1840, 444 – 5th Ave., SW Calgary, AB T2P 2T8 Canada | |
| Phone | (587) 577-9261 |
| Website | firstpersongroup.com |
Stock Details
| Ticker Symbol | FP |
| Exchange | NASDAQ |
| Reporting Currency | USD |
| CIK Code | 0001900035 |
| Employer ID | 86-1728349 |
| SIC Code | 2833 |
Key Executives
| Name | Position |
|---|---|
| Cory J. Rosenberg | Chairman, Chief Executive Officer, and President |
| Darcy A. Campbell | Chief Financial Officer |
| Adam J. Schoenberg | Chief Marketing Officer |
| Chris L. Claussen | Director and Chief Innovation Officer |
| Ariel Fainsod | Director |
| Gail D. Hamilton Azodo | Director |
| Rosema J. Nemorin | Director |
| Robert C. Kaelin | Head of Mycology & Psychedelics |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 8, 2024 | RW | Filing |
| Oct 20, 2023 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Sep 29, 2023 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Sep 13, 2023 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jul 11, 2023 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| May 2, 2023 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Apr 13, 2023 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Feb 8, 2023 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jan 13, 2023 | D | Notice of Exempt Offering of Securities |
| Oct 17, 2022 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |